Year: 2023

logo-15

Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity"...

logo-15

Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity"...

logo-15

Asia Pacific Spintronics Market Report to 2031: Players Include Avalanche Technology, Crocus Technology, Everspin Technologies, IBM and Intel – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Spintronics Market 2021-2031 by Device Type, Application, Industry Vertical, and Country: Trend Forecast and Growth Opportunity"...

TAT-2

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to...

TAT-1

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to...

TAT

Sumitomo Heavy Industries, Ltd. invests in Alpha Fusion Inc., developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy

TOKYO--(BUSINESS WIRE)--Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to...

New_Bio-Thera_Logo-3

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase...

New_Bio-Thera_Logo-2

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase...

New_Bio-Thera_Logo-1

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

GUANGZHOU, China--(BUSINESS WIRE)--#ADC--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase...